Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
beta blocker |
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
C07AB12
|
| gptkbp:brand |
gptkb:Bystolic
Nebilet Nebivololum |
| gptkbp:CASNumber |
118457-14-0
|
| gptkbp:contraindication |
severe bradycardia
severe liver impairment cardiogenic shock |
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
nebivolol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-1 adrenergic receptor antagonist
vasodilation via nitric oxide release |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
98%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue headache bradycardia |
| gptkbp:usedFor |
heart failure
hypertension |
| gptkbp:bfsParent |
gptkb:Beta-1_adrenergic_receptor
|
| gptkbp:bfsLayer |
7
|